EFS is a public body and the national blood service and the main actor for cellular therapy and development of ATMPs in France. Currently, EFS mainly ensures the production of pancreatic islets through the GRAGIL consortium and the production of MSCs as ATMPs in France through coordination of national production platform of ECELL France program. EFS, with its platform EFS Rhône-Alpes in Saint Ismier is equipped with a GMP manufacturing platform for Advanced Therapy Medicinal products (ATMP).
The Cell Therapy and Engineering Unit has an expertise in the transfer of manufacturing processes from research to clinical cell therapy, in the upscaling and optimization of of manufacturing processes for cell therapy medicines used in clinical trials and for regulatory issues regarding ATMP and cell therapy products
Cell Therapy and Engineering Unit - EFS Rhone Alpes
Route de Lancey 464
38330 St Ismier
Dr. Anaick Moisan
The people involved in the project are
Dr Anaïck Moisan, PharmD and PhD, is the pharmacist responsible for the development and the release of ATMP used in regenerative medicine (MSCs, encapsulated human pancreatic islets) and immunotherapy (dendritic cells) clinical trials, in the Cell Therapy and Engineering Unit (EFS Rhône Alpes Auvergne, St Ismier).
Dr Virginie Persoons, Pharm D, is the pharmacist, responsible for the activity of Hematopoietic stem cells transplantation and for the quality control of ATMP in the Cell Therapy and Engineering Unit.
Dr Harald Egelhofer, PharmD, is the pharmacist responsible for the production of ATMP and Hematopoietic stem cells in the Cell Therapy and Engineering Unit.
Dr Egelhofer and Dr Persoons have developed the isolation of human pancreatic islets in the Cell Therapy and Engineering Unit in 2002 and the isolation of pancreatic islet for clinical grafts through the GRAGIL consortium is running since 2008.